HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 314-319

  Reina, Samantha A ^a   Llabre, Maria M ^a   Allison, Matthew A ^b   Wilkins, John T ^c   Mendez, Armando J ^d   Arnan, Martinson K ^e   Schneiderman, Neil ^a   Sacco, Ralph L ^d   Carnethon, Mercedes ^c   Chris Delaney, J A ^f  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cholesterol; Lipids; Risk factors for stroke

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ASIAN AMERICAN; ATHEROSCLEROSIS; BLACK PERSON; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PARTICLE SIZE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; AFRICAN AMERICAN; BLOOD; ETHNIC GROUP; ETHNOLOGY; MULTIVARIATE ANALYSIS; RISK FACTOR; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; STROKE; UNITED STATES;

EID: 84942761786     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.09.031     Document Type: Article

References (36)

1. Rye K.A., et al. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 2009, 50(Suppl. l):S195-S200.
2. Akinkuolie A.O., et al. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ. Cardiovasc Qual. Outcomes 2014, 7(1):55-63.
3. Rohatgi A., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 2014, 371(25):2383-2393.
4. Gordon D.J., Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N. Engl. J. Med. 1989, 321(19):1311-1316.
5. Lindenstrom E., Boysen G., Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994, 309(6946):11-15.
6. Tanne D., Yaari S., Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997, 28(1):83-87.
7. Shahar E., et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2003, 34(3):623-631.
8. Woodward M., et al. Associations between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. Eur. Heart J. 2007, 28(21):2653-2660.
9. Bots M.L., et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J. Epidemiol. Community Health 2002, 56. Suppl 1: p. i19-24.
10. Willey J.Z., et al. Lipid profile components and risk of ischemic stroke: the Northern Manhattan Study (NOMAS). Arch. Neurol. 2009, 66(11):1400-1406.
11. Berger J.S., et al. Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women. Stroke 2012, 43(4):958-966.
12. Zeljkovic A., et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010, 210(2):548-554.
13. Ridker P.M., et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010, 376(9738):333-339.
14. Haffner S.M., et al. The role of behavioral variables and fat patterning in explaining ethnic differences in serum lipids and lipoproteins. Am. J. Epidemiol. 1986, 123(5):830-839.
15. Burchfiel C.M., et al. Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study. Am. J. Epidemiol. 1990, 131(1):57-70.
16. Powell K.E., et al. Physical activity and the incidence of coronary heart disease. Annu. Rev. Public Health 1987, 8:253-287.
17. Bild D.E., et al. Multi-ethnic study of atherosclerosis: objectives and design. Am. J. Epidemiol. 2002, 156(9):871-881.
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18(6):499-502.
19. Mackey R.H., et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 2012, 60(6):508-516.
20. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26(4):847-870.
21. Mora S., et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119(7):931-939.
22. Degoma E.M., et al. Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013, 229(2):517-523.
23. Rader D.J., Hovingh G.K. HDL and cardiovascular disease. Lancet 2014, 384(9943):618-625.
24. Rye K.-A., Barter P.J. Regulation of high-density lipoprotein metabolism. Circ. Res. 2014, 114(1):143-156.
25. Schaefer E.J., Anthanont P., Asztalos B.F. High-density lipoprotein metabolism, composition, function, and deficiency. Curr. Opin. Lipidol. 2014, 25(3):194-199.
26. Kotur-Stevuljevic J., et al. Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients. Atherosclerosis 2015, 241(1):192-198.
27. Rader D.J. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 2003, 92(4A):42J-49J.
28. Miyazaki A., et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 1995, 15(11):1882-1888.
29. Rubin E.M., et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991, 353(6341):265-267.
30. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(20):9607-9611.
31. Paszty C., et al. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 1994, 94(2):899-903.
32. Liu A.C., et al. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J. Lipid Res. 1994, 35(12):2263-2267.
33. Benoit P., et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999, 99(1):105-110.
34. Tangirala R.K., et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999, 100(17):1816-1822.
35. Medina M.W., Krauss R.M. The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc Med. 2009, 19(5):173-177.
36. American Heart Association Types of Stroke [cited 2014 07/14/2014]; Available from:. http://www.strokeassociation.org/STROKEORG/AboutStroke/TypesofStroke/Types-of-Stroke_UCM_308531_SubHomePage.jsp.